source
- FDA staff say Replimune's melanoma trial fails to demonstrate efficacyFDA staff reviewing Replimune's pivotal melanoma study concluded that the trial design did not provide sufficient evidence that the RP1 therapy works. The assessment was issued ahead of a schedule…
- Alnylam shares tumble 30% even as biotech sector ralliesAlnylam's stock fell about 30% on July 28, 2026, even though the broader biotech market is experiencing a resurgence. The market rebound follows years of a bearish environment, with increased merg…